Selective biologics for ulcerative colitis and Crohns disease
Petkau JM, Eksteen B (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - March 8, 2016 Category: Biochemistry Source Type: research
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell disease characterized by the presence of the Philadelphia chromosome and the bcr-abl gene. The discovery of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now possible. Due to resista...
Source: Biologics: Targets and Therapy - February 26, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Management of Philadelphia chromosome positive chronic myelogenous leukemia
Emole J, Talabi T, Pinilla-Ibarz J (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - February 25, 2016 Category: Biochemistry Source Type: research
Biosimilars in the management of neutropenia: focus on filgrastim
Désirée Caselli,1 Simone Cesaro,2 Maurizio Aricò1 1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human gra...
Source: Biologics: Targets and Therapy - February 18, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Biosimilars in the management of neutropenia
Caselli D, Cesaro S, Aricò M (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - February 17, 2016 Category: Biochemistry Source Type: research
Emerging treatments in Castleman disease & ndash; a critical appraisal of siltuximab
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - January 24, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a chimeric monoclonal antibody to IL-6, has thus emerged as a promising treatment option in a disease lacking efficacious therapy. Here, we review the findings of recent studies evaluating single...
Source: Biologics: Targets and Therapy - January 24, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Emerging treatments in Castleman disease
Koff JL, Lonial S (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - January 24, 2016 Category: Biochemistry Source Type: research
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
Roberto Guariglia,1 Maria Carmen Martorelli,1 Rosa Lerose,2 Donatella Telesca,2 Maria Rita Milella,2 Pellegrino Musto3 1Unit of Hematology and Stem Cell Transplantation, 2Pharmacy Service, 3Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy Abstract: Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowi...
Source: Biologics: Targets and Therapy - January 22, 2016 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Lipegfilgrastim in chemotherapy-induced neutropenia
Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - January 21, 2016 Category: Biochemistry Source Type: research
Drug usage analysis and health care resources consumption in na & iuml;ve patients with rheumatoid arthritis
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 5, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis
Conclusion: The role of biologic therapies in the treatment of RA continues to evolve; our study reflects real-world drug utilization data in adult patients with RA. These observations could be used by decision makers to support formulary decisions, although further research is needed using a larger sample to validate these results.Keywords: rheumatoid arthritis, biologic agents, real-world data (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 5, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options & ndash; role of smoothened inhibitors
(Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 5, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors
Leslie A Fecher,1,3 William H Sharfman2 1Department of Internal Medicine and Dermatology, Indiana University Health Simon Cancer Center, Indianapolis, IN, USA; 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA, 3Department of Internal Medicine and Dermatology, University of Michigan, MI, USA Abstract: Cutaneous basal cell carcinoma (BCC) is the most common human cancer and its incidence is rising worldwide. Ultraviolet radiation exposure, including tanning bed use, as well as host factors play a role in its development. The majority of cases are treated and cured with local therapies incl...
Source: Biologics: Targets and Therapy - November 5, 2015 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Health care resources for patients with rheumatoid arthritis
Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L (Source: Biologics: Targets and Therapy)
Source: Biologics: Targets and Therapy - November 5, 2015 Category: Biochemistry Source Type: research
